Coadministration of Stribild and some medicinal products that are primarily metabolised by CYP3A may result in increased plasma concentrations of these products, which are associated with the potential for serious and/or life-threatening reactions such as peripheral vasospasm or ischaemia (e.g., dihydroergotamine, ergotamine, ergometrine).
Stribild Summary of Product Characteristics, Gilead Sciences International Ltd, November 2021.

Coadministration may increase concentrations of ergot derivatives. Coadministration of Stribild is contraindicated due to potential for serious and/or life-threatening events such as acute ergot toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues.